Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

NCT06635850 is registered in ClinicalTrials.gov with Pulmovant, Inc. as lead sponsor.

NCT NCT06635850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06635850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Lead sponsor
Pulmovant, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 29, 2024
Completion date
January 31, 2028
Enrollment
135 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, fibrosis, interstitial lung disease, lung diseases, pulmonary hypertension, vascular diseases